The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT04415385
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    200mg, intravenous infusion for 30 minutes (including the time of the tube, the overall infusion time is not shorter than 20 minutes, no longer than 60 minutes), once every 2 weeks.
  • Apatinib — DRUG
    250 mg, orally once a day. Take about half an hour after a meal with warm water.

Study Details

This is an single arm, open-label, phase II trial to evaluate safety and efficacy of using the combination of Camrelizumab with apatinib as second-line therapy for advanced PDAC.

Key Dates

Start date
Jun 1, 2020
Status verified
May 2020
Primary completion
Jun 1, 2022
Completion
Jun 1, 2023

Study Design

Enrollment
48 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab + Apatinib
    Participants receive Camrelizumab 200mg intravenously every 2 weeks and apatinib 250mg orally once daily until disease progression or unacceptable toxicity

Primary Outcome Measure

ORR [ Time Frame: Through study completion, an average of 2 years. ]

Central Contacts

Related Studies